Frequency and Effective Factors on Discontinuation of Treatment in Patients with Inflammatory Rheumatic Diseases

Authors

  • Mobini, Maryam Associate Professor, Department of Internal Medicine, Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, Iran
  • Mohammadpour , Reza Ali Professor, Department of Biostatistics, Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Abstract:

Background and purpose: Treatment of rheumatic diseases depends on proper use of medications. The aim of this study was to evaluate the frequency and reasons for discontinuation of drugs in these patients. Materials and methods: A cross-sectional study was performed in patients with inflammatory rheumatic diseases in Sari, Iran 2020-2021 to investigate the frequency and reasons for discontinuation of drugs. Statistical analysis was performed using SPSS V20 and descriptive statistical methods were used to determine the frequency of drug discontinuation and its causes. Results: The participants (n=251) included 197 patients with rheumatoid arthritis, 31 with systemic lupus, 16 with ankylosing spondylitis, and 7 patients with psoriatic arthritis. The mean age of patients was 52.36±13.4 and mean duration of illness was 8.35±7.31 years. Drug discontinuation was seen in 73 patients (85 cases). The most common reason for drug discontinuation was drug side effects (55.4%). Drug shortage, transient improvement of symptoms, ineffectiveness of the drug, and fear of developing COVID 19 were some of the reasons for discontinuation of drug. Conclusion: The most common cause of discontinuation of treatment was drug side effects, but in about one third of cases, there are factors that could be corrected to help preventing drug discontinuation and non-adherence to treatment.  

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases

In this study, we compare the health-related quality of life (HRQoL) of patients with moderate-to-severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS), and study the effect of treatment with infliximab on the HRQoL of patients with these diseases. Short Form Health Survey-36 (SF-36) data from the placebo-controlled phases of 4 studies of infliximab in pat...

full text

Correction to: Effective Factors on Delayed Onset of Treatment in Patients with Acute Myocardial Infarction

Correction to: Effective Factors on Delayed Onset of Treatment in Patients with Acute Myocardial Infarction     Ensiyeh Rezaee1, Nasrin Hanifi2, Mahin Rohani3, Soghrat Faghih Zadeh4   1 MSc Student in Critical Care Nursing, Faculty of Nursing and Midwifery, Zanjan University of Medical Sciences, Zanjan, Iran 2 Assistant Professor, Department of  Critical Care Nursing, Faculty of Nursin...

full text

Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases

The aim of this study was to determine whether inflammation is related to cancer development, and whether the incidence of cancer is increased and occurs in a site-specific manner in patients with systemic autoimmune rheumatic diseases (SARDs).This study included a nationwide dynamic cohort of patients with various newly diagnosed SARDs from 1997 to 2010 with follow-up until 2012.This study inc...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 32  issue 208

pages  145- 150

publication date 2022-04

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023